Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.

Cancer letters - 1 Oct 2018

Zhang Huijuan, Han Bing, Lu Hailing, Zhao Yanbin, Chen Xuesong, Meng Qingwei, Cao Mengru, Cai Li, Hu Jing

Abstract excerpt

As a newly discovered deubiquitinating enzyme, ubiquitin-specific protease 22 (USP22) is predictive of therapeutic outcomes in individual cancer patients. However, its clinical effects on malignancy and its roles in conferring resistance to EGFR-TKIs (epidermal growth factor receptor-tyrosine kinase inhibitors) in lung adenocarcinoma (ADC) remain largely unknown. Here, we showed that USP22 promotes cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Neoplasm Transplantation

Share to Protein Kinase Inhibitors

Share to Proteolysis

Share to Thiolester Hydrolases

Share to Ubiquitin Thiolesterase

Source

Identifiers

PMID: 29981430
DOI: 10.1016/j.canlet.2018.07.002

Genes

EGFR
USP22
EGF
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.PMID 29981430Read ↗

Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma.Semantic proximity Read ↗

USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung CancerSemantic proximity Read ↗

Targeting deubiquitinase USP28 for cancer therapySemantic proximity Read ↗

Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung CancerSemantic proximity Read ↗

Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatmentSemantic proximity Read ↗

USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer ProgressionSemantic proximity Read ↗

USP7 deubiquitinates KRAS and promotes non-small cell lung cancer.Semantic proximity Read ↗

Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expressionSemantic proximity Read ↗

Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-CateninSemantic proximity Read ↗

Targeting USP13 ‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancerSemantic proximity Read ↗

Deubiquitinating enzyme USP22 positively regulates c‐Myc stability and tumorigenic activity in mammalian and breast cancer cellsSemantic proximity Read ↗

The emerging role of ubiquitin-specific protease 20 in tumorigenesis and cancer therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.